Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.
about
Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developmentsPharmacology of anticoagulants used in the treatment of venous thromboembolismCatheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatmentEnoxaparin use in pregnancy: state of the art.Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.Enoxaparin use in the neonatal intensive care unit: experience over 8 years.Clinical pharmacology of antithrombotic drugs in coronary artery disease.Safety evaluation of enoxaparin in currently approved indications.Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?Low-molecular-weight heparin overdose: management by observation.Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients.Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.A practical approach to the use of low molecular weight heparins in VTE treatment and prophylaxis in children and newborns.Dosing of Enoxaparin in Renal Impairment.Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay.Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects.Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome.Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism.Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism.Increased unfractionated heparin requirements with decreasing body mass index in pregnancy.Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment.
P2860
Q26862694-BDF7C88A-E089-4E71-BFC0-59982C249704Q28078967-BE8DD4C9-7F0A-477B-9C0F-62B0118CF6C5Q28217792-1F38ABCB-5387-4387-875C-FB007179EA51Q33386499-601C648D-D5DF-4E03-B518-3BF419C1EF67Q34549913-7B30FC89-D6A2-4FED-90DB-9554A059FC88Q36920696-5F578F29-27F8-40EB-A85B-5D968855FB6DQ37591007-EF2BD637-EE4D-4616-93AC-9A85D4368CB4Q37622250-F1E3C07D-BA66-4D5D-A7F9-BEA8DC656C51Q37701972-4FF4828B-D5C4-4A4C-8AB4-7641E4777EBBQ37798093-78F689DB-EDA7-4BAA-986C-7AF033BF13BFQ38000187-886DD9DC-5503-4E69-BF3D-15E2F32F889EQ38029256-71400D6E-A499-484F-85AD-194CD558416EQ38261097-1F9E3E9C-EF18-41CC-95E4-AF80CE110933Q38851458-D09756B8-8478-4540-BCBD-A018C2E04AC0Q38869704-E09710C6-FE97-4AC1-8BFB-AC2F87BB519FQ39816187-1DD26DDA-6EB3-4EE2-985E-3652547CD357Q40087127-DDC2AA3C-D051-4D4C-992A-5C55EDBD8BE4Q42387444-BAF2994C-4316-4051-9617-99102889E33FQ45178257-9B0F59DA-F6DE-49FB-A6BE-B79AC89FC226Q47133992-3C0DFF81-8E13-4DB3-B023-D947032D0B5FQ50323429-195631B1-7D11-457C-B5FC-D9E8C98C97EDQ55455218-A1AD9E3E-5B1B-4343-BDBC-2806F6B24802
P2860
Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Pharmacodynamic and pharmacoki ...... cations for clinical practice.
@ast
Pharmacodynamic and pharmacoki ...... cations for clinical practice.
@en
type
label
Pharmacodynamic and pharmacoki ...... cations for clinical practice.
@ast
Pharmacodynamic and pharmacoki ...... cations for clinical practice.
@en
prefLabel
Pharmacodynamic and pharmacoki ...... cations for clinical practice.
@ast
Pharmacodynamic and pharmacoki ...... cations for clinical practice.
@en
P2093
P1476
Pharmacodynamic and pharmacoki ...... cations for clinical practice.
@en
P2093
Debra Hoppensteadt
Jawed Fareed
Jeanine Walenga
Omer Iqbal
Taqdees Sheikh
Walter Jeske
P304
P356
10.2165/00003088-200342120-00003
P50
P577
2003-01-01T00:00:00Z
P6179
1034978185